JP2018529766A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529766A5
JP2018529766A5 JP2018534488A JP2018534488A JP2018529766A5 JP 2018529766 A5 JP2018529766 A5 JP 2018529766A5 JP 2018534488 A JP2018534488 A JP 2018534488A JP 2018534488 A JP2018534488 A JP 2018534488A JP 2018529766 A5 JP2018529766 A5 JP 2018529766A5
Authority
JP
Japan
Prior art keywords
use according
testing
serum
patient
single oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018534488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529766A (ja
JP6816149B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052800 external-priority patent/WO2017053373A1/en
Publication of JP2018529766A publication Critical patent/JP2018529766A/ja
Publication of JP2018529766A5 publication Critical patent/JP2018529766A5/ja
Application granted granted Critical
Publication of JP6816149B2 publication Critical patent/JP6816149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018534488A 2015-09-21 2016-09-21 成長ホルモン欠乏症の検出および治療 Active JP6816149B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US62/221,191 2015-09-21
US201662289221P 2016-01-30 2016-01-30
US62/289,221 2016-01-30
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020213095A Division JP7104768B2 (ja) 2015-09-21 2020-12-23 成長ホルモン欠乏症の検出および治療

Publications (3)

Publication Number Publication Date
JP2018529766A JP2018529766A (ja) 2018-10-11
JP2018529766A5 true JP2018529766A5 (https=) 2019-08-15
JP6816149B2 JP6816149B2 (ja) 2021-01-20

Family

ID=58276481

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018534488A Active JP6816149B2 (ja) 2015-09-21 2016-09-21 成長ホルモン欠乏症の検出および治療
JP2020213095A Active JP7104768B2 (ja) 2015-09-21 2020-12-23 成長ホルモン欠乏症の検出および治療
JP2022110116A Active JP7389862B2 (ja) 2015-09-21 2022-07-08 成長ホルモン欠乏症の検出および治療
JP2023195764A Active JP7724831B2 (ja) 2015-09-21 2023-11-17 成長ホルモン欠乏症の検出および治療
JP2025130430A Pending JP2025170274A (ja) 2015-09-21 2025-08-05 成長ホルモン欠乏症の検出および治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020213095A Active JP7104768B2 (ja) 2015-09-21 2020-12-23 成長ホルモン欠乏症の検出および治療
JP2022110116A Active JP7389862B2 (ja) 2015-09-21 2022-07-08 成長ホルモン欠乏症の検出および治療
JP2023195764A Active JP7724831B2 (ja) 2015-09-21 2023-11-17 成長ホルモン欠乏症の検出および治療
JP2025130430A Pending JP2025170274A (ja) 2015-09-21 2025-08-05 成長ホルモン欠乏症の検出および治療

Country Status (23)

Country Link
US (5) US9763919B2 (https=)
EP (3) EP3939590B1 (https=)
JP (5) JP6816149B2 (https=)
KR (4) KR20230116961A (https=)
CN (2) CN116459250A (https=)
AU (5) AU2016328969B2 (https=)
CA (1) CA2998523C (https=)
CY (1) CY1125183T1 (https=)
DK (2) DK3939590T3 (https=)
ES (2) ES2967259T3 (https=)
FI (1) FI3939590T3 (https=)
HR (1) HRP20220317T1 (https=)
HU (2) HUE057831T2 (https=)
IL (1) IL258224B (https=)
LT (1) LT3352752T (https=)
PL (2) PL3939590T3 (https=)
PT (2) PT3939590T (https=)
RS (1) RS62988B1 (https=)
SG (2) SG10202010598SA (https=)
SI (1) SI3352752T1 (https=)
SM (1) SMT202200167T1 (https=)
UA (1) UA123865C2 (https=)
WO (1) WO2017053373A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016328969B2 (en) * 2015-09-21 2020-10-08 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
JP2021535203A (ja) 2018-08-20 2021-12-16 ベッソール ファルマ、エルエルシー 既知および新規カンナビノイドの適用
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2139326A1 (en) * 1992-06-29 1994-01-06 Barry B. Bercu Diagnostic procedure for evaluating short stature etiology
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6864250B1 (en) 1997-08-22 2005-03-08 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
ATE370119T1 (de) 2000-06-13 2007-09-15 Zentaris Gmbh Wachstumhormonsekretionsförderer
EP1667671A1 (en) * 2003-09-19 2006-06-14 Pfizer Health AB Enhanced method of treatment of growth disorders
SG134333A1 (en) 2003-11-12 2007-08-29 Phenomix Corp Heterocyclic boronic acid compounds
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
AU2016328969B2 (en) * 2015-09-21 2020-10-08 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency

Similar Documents

Publication Publication Date Title
JP2018529766A5 (https=)
Morimoto et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment
CA2688766C (en) Compositions and methods for treatment of multiple sclerosis
US20190262263A1 (en) Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions
EP2338516A3 (en) Multiple-variable dose regimen for treating TNF-alpha-related disorders
JP2015520188A5 (https=)
FI3939590T3 (fi) Kasvuhormonin puutoksen tunnistaminen ja hoitaminen
JP2023531675A5 (https=)
JP2019533672A5 (https=)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
CN105769876B (zh) 胆汁酸成分及熊胆的医药用途
Rathbone et al. Design and development of systemic oral mucosal drug delivery systems
Akhmedzhanova et al. Diagnosis and treatment of chronic pelvic pain syndrome
Qin et al. JCM‐16021, a Chinese Herbal Formula, Attenuated Visceral Hyperalgesia in TNBS‐Induced Postinflammatory Irritable Bowel Syndrome through Reducing Colonic EC Cell Hyperplasia and Serotonin Availability in Rats
AU2015305430A1 (en) Method for treating hyperhidrosis
Ahmadi et al. Guillain–Barre syndrome: a prevalent autoimmune disease during the coronavirus disease-2019 pandemic
JP2019001830A (ja) 医薬
SU1205915A1 (ru) Способ лечени аллергических заболеваний
NZ741142B2 (en) Detecting and treating growth hormone deficiency
Stoll et al. Severe acute inflammatory demyelinating polyradiculoneuropathy with persistent weakness associated with tumor-like nerve root enlargement
Urokovich Combination therapy of the bronchial hyperresponsiveness
Meti Ramosetron vs Palonosetron in Preventing Postoperative Nausea and Vomiting in Laparoscopic Surgeries-A Clinical Comparision
Erskine et al. P151 The role of self-administered icatibant in the diagnosis of hereditary angioedema with normal C1 esterase
JP2022513666A5 (https=)
Prenner et al. A Post-Hoc Analysis Of Asthma Control And Lung Function Following Treatment With Ciclesonide 80 μg HFA-MDI Twice Daily In Subjects With Mild-to-Moderate Persistent Asthma Previously Receiving Low Dose Fluticasone Propionate/Salmeterol